Essex Woodlands Healthcare Partners

What Essex Woodlands Healthcare Partners does

Essex Woodlands Healthcare Partners, doing business as EW Healthcare Partners, is a US-based healthcare-focused growth equity and venture capital firm founded in 1985. The firm partners with management teams of middle-market healthcare companies that are EBITDA-positive or approaching profitability in the United States and Europe, deploying capital through minority or majority positions and providing strategic guidance, board representation, and operating support across pharmaceuticals, MedTech, and tech-enabled services sectors. Its portfolio spans over 150 historical investments, with recent platforms including Germfree Laboratories (modular cleanrooms), Grundium Oy (digital pathology imaging), Enercon Technologies (medical device manufacturing), Boiron Group (French natural medicine), Laboratoires Majorelle (French specialty pharma), VitalConnect (remote cardiac monitoring), BioTissue, MIMEDX, and Prolacta; notable exits include EUSA Pharma (sold to Recordati for approximately €750M) and Cognate BioServices (sold to Charles River Laboratories for $875M).

The firm generates revenue through management fees on committed capital across multiple fund vehicles (Fund 1, Fund 2, Fund 3 and a continuation fund) plus carried interest on profitable exits, sourced from institutional Limited Partners through private placement. It is an SEC-registered investment adviser under the Investment Advisers Act of 1940 and operates a UK-regulated entity (Essex Woodlands Health Ventures UK Limited, FCA Appointed Representative of Sentinel Regulatory Services Ltd). The investment team, operating partners and senior advisors are distributed across offices in New York, London and Houston; leadership as of late 2024 comprises Dr. Petri Vainio (Executive Chairman), Dr. Evis Hursever (CEO), Scott Barry (COO), and Marty Sutter (Founding Partner). The firm does not develop proprietary technology products; its differentiation lies in healthcare sector specialization, deep operating expertise, and a 35+ year track record of capital deployment across healthcare sub-sectors and geographies.

Name

Essex Woodlands Healthcare Partners

Legal name

Essex Woodlands Management, Inc.

Website

https://www.ewhealthcare.com

Company type

Private

Founded year

1985

Operating status

Operating

Headcount range

11–50 employees

Short description

Essex Woodlands Healthcare Partners is a healthcare-focused growth equity firm founded in 1985 that invests minority and majority capital in middle-market US and European healthcare companies, partnering with management teams across pharma, MedTech, and tech-enabled services.

Ownership category

akta.pro rank

Product category

Healthcare Growth Equity Investment

NAICS

Portfolio Management and Investment Advice (523940), All Other Financial Investment Activities (52399)

SIC

Investment Advice (6282)

akta.pro primary industry

Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

• Healthcare growth equity
• Venture capital investing
• Private equity firm
• Life sciences investment
• Healthcare buyout

Headquarters

HQ city

Palo Alto

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

1. Management Fees: Charged on committed capital under management across multiple funds raised since 2014.
2. Carried Interest / Performance Fees: Performance-based fees earned on fund returns when investments are exited profitably.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

EW Healthcare Partners (Essex Woodlands Healthcare Partners) is a private growth equity and venture capital firm that invests growth equity capital in middle-market healthcare and life sciences companies in the US and Europe. The firm partners with experienced management teams, takes minority or majority positions in EBITDA-positive or near-profitable companies, and provides strategic guidance, board participation, M&A support and operational expertise through its investment professionals, operating partners and senior advisors.

Product overview

EW Healthcare Partners is a healthcare growth equity investment firm, not a product or technology company. The firm provides growth equity capital and strategic guidance to healthcare and life sciences companies across pharmaceuticals, medical devices, diagnostics, and technology-enabled services sectors. The firm's investment strategy focuses on partnering with management teams of middle-market, EBITDA-positive or soon-to-be companies in the US and European health sectors. EW Healthcare Partners does not offer a unified product platform but rather provides investment capital, operational expertise, and strategic guidance through its team of investment professionals, operating partners, and senior advisors. The firm's portfolio includes companies such as Germfree (modular cleanroom facilities), Boiron (natural medicine), Enercon Technologies (medical device manufacturing), and Prolacta/BioTissue (human milk-based nutritional products and regenerative medicine).

Differentiator

Problem solved

Functional benefit

Products and services

• EW Healthcare Partners Fund 1
• EW Healthcare Partners Fund 2
• EW Healthcare Partners Fund 3
• EW Healthcare Partners Continuation Fund
• Growth Equity Investment and Strategic Advisory

Quantifiable outcome

• Over $2 billion of capital raised since 2014 across three growth equity funds and one continuation fund
• +1 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Orgenesis Inc.coreStrategic or Co-development Partner · 10 April 2024Germfree and Orgenesis entered into an asset purchase and strategic partnership to co-market Orgenesis' decentralized Octomera service platform and OMPULs (Octomera Mobile Processing Units and Labs) globally. Germfree markets, manufactures, and services OMPULs as part of its modular cleanroom fleet, enabling Orgenesis to focus on its therapeutic pipeline in immuno-oncology. The collaboration aims to significantly reduce production costs of cell and gene therapy products and make treatments more affordable and accessible worldwide.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/73860

Revenue estimate

Valuation estimate

Number of profiles

Profiles16 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Investments133 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Essex Woodlands Healthcare Partners